Evotec AG-Product Pipeline Review-2015

Evotec AG-Product Pipeline Review-2015

  • Products Id :- GMDHC06992CDB
  • |
  • Pages: 56
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Evotec AG-Product Pipeline Review-2015


Global Markets Direct's, 'Evotec AG-Product Pipeline Review-2015', provides an overview of the Evotec AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Evotec AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Evotec AG including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Evotec AG's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Evotec AG's pipeline products

Reasons To Buy

Evaluate Evotec AG's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Evotec AG in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Evotec AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Evotec AG and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Evotec AG

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Evotec AG and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Evotec AG Snapshot 7

Evotec AG Overview 7

Key Information 7

Key Facts 7

Evotec AG-Research and Development Overview 8

Key Therapeutic Areas 8

Evotec AG-Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products-Monotherapy 12

Pipeline Products-Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Pipeline Products-Out-Licensed Products 15

Out-Licensed Products/Combination Treatment Modalities 16

Evotec AG-Pipeline Products Glance 17

Evotec AG-Clinical Stage Pipeline Products 17

Phase II Products/Combination Treatment Modalities 17

Phase I Products/Combination Treatment Modalities 18

Evotec AG-Early Stage Pipeline Products 19

Preclinical Products/Combination Treatment Modalities 19

Discovery Products/Combination Treatment Modalities 20

Evotec AG-Drug Profiles 21

EVT-201 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

EVT-401 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Drug to Inhibit KDM for Oncology 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Drugs for Endometriosis 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Drugs for Multiple Sclerosis 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

EVT-501 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Small Molecule to Antagonize P2X3 and P2X2/3 for Inflammatory Pain, Neuropathic Pain and Urinary Incontinence 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Small Molecule to Inhibit PDE10a for Schizophrenia and Psychosis 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Small Molecules for Pain 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Drug for Kidney Diseases 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Drugs for Alzheimer's Disease 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Drugs to Inhibit FGFR3 for Bladder Cancer 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Drugs to Inhibit Isocitrate Dehydrogenase for Cancer 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Drugs to Target EEM for Type 1 Diabetes and Type 2 Diabetes 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Induced Pluripotent Stem Cells for Amyotrophic Lateral Sclerosis 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Small Molecule to Inhibit PGB for Bacterial Infections 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Small Molecules for Chronic Kidney Disease 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Small Molecules for Dysferlinopathies 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Small Molecules for Glioblastoma Multiforme 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Small molecules for Huntington Disease 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Small Molecules for Inflammation 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Small Molecules for Multiple Sclerosis 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Small Molecules for Neurodegeneration 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Small Molecules for Solid Tumor and Leukemia 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Evotec AG-Pipeline Analysis 45

Evotec AG-Pipeline Products by Target 45

Evotec AG-Pipeline Products by Route of Administration 46

Evotec AG-Pipeline Products by Molecule Type 47

Evotec AG-Pipeline Products by Mechanism of Action 48

Evotec AG-Recent Pipeline Updates 49

Evotec AG-Dormant Projects 50

Evotec AG-Discontinued Pipeline Products 51

Discontinued Pipeline Product Profiles 51

EVT-301 51

RG-1577 51

ocaperidone 51

REN-1654 51

REN-213 51

REN-850 51

Evotec AG-Company Statement 52

Evotec AG-Locations And Subsidiaries 53

Head Office 53

Other Locations & Subsidiaries 53

Appendix 55

Methodology 55

Coverage 55

Secondary Research 55

Primary Research 55

Expert Panel Validation 55

Contact Us 55

Disclaimer 56

List of Tables

Evotec AG, Key Information 7

Evotec AG, Key Facts 7

Evotec AG-Pipeline by Indication, 2015 9

Evotec AG-Pipeline by Stage of Development, 2015 11

Evotec AG-Monotherapy Products in Pipeline, 2015 12

Evotec AG-Partnered Products in Pipeline, 2015 13

Evotec AG-Partnered Products/ Combination Treatment Modalities, 2015 14

Evotec AG-Out-Licensed Products in Pipeline, 2015 15

Evotec AG-Out-Licensed Products/ Combination Treatment Modalities, 2015 16

Evotec AG-Phase II, 2015 17

Evotec AG-Phase I, 2015 18

Evotec AG-Preclinical, 2015 19

Evotec AG-Discovery, 2015 20

Evotec AG-Pipeline by Target, 2015 45

Evotec AG-Pipeline by Route of Administration, 2015 46

Evotec AG-Pipeline by Molecule Type, 2015 47

Evotec AG-Pipeline Products by Mechanism of Action, 2015 48

Evotec AG-Recent Pipeline Updates, 2015 49

Evotec AG-Dormant Developmental Projects,2015 50

Evotec AG-Discontinued Pipeline Products, 2015 51

Evotec AG, Subsidiaries 53

List of Figures

Evotec AG-Pipeline by Top 10 Indication, 2015 9

Evotec AG-Pipeline by Stage of Development, 2015 11

Evotec AG-Monotherapy Products in Pipeline, 2015 12

Evotec AG-Partnered Products in Pipeline, 2015 13

Evotec AG-Out-Licensed Products in Pipeline, 2015 15

Evotec AG-Pipeline by Top 10 Target, 2015 45

Evotec AG-Pipeline by Top 10 Molecule Type, 2015 47

Evotec AG-Pipeline Products by Top 10 Mechanism of Action, 2015 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Current R&D Portfolio of Evotec AG; Evotec AG - Key Therapeutics; Evotec AG - Pipeline Overview and Promising Molecules; Evotec AG - News; Evotec AG - Latest Updates; Evotec AG - Pipeline; Evotec AG - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 102450
Site License
USD 3000 INR 204900
Corporate User License
USD 4500 INR 307350



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com